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Abstract: In 2008 and the years that followed, 
Europe experienced a severe economic crisis, 
which presented a grave challenge to public 
finances. This report examines public 
expenditures on public order and safety, health 
and social protection, as these are the areas 
where most drug-related activities and services 
are provided. It concludes, first, that austerity led 
to reductions in spending in those categories of 
government activity that encompass most drug-
related initiatives; second, that countries that 
experienced greater levels of austerity tended to 
show greater reductions in expenditure; and, 
third, that bigger cuts in public expenditure were 
registered in health than in public safety and 
social protection. The available national estimates 
of drug-related public expenditure do not reveal 
the full impact of the 2008–09 economic 
recession on the public financing of drug policy in 
Europe. However, it is possible to conclude that 
the impact of austerity on drug policy was more 
severe in the countries that were hardest hit by 
the economic crisis. Nevertheless, in most 
European countries, recession has led to a 
reassessment of public financing of specific drug 
policies and often to their adjustment. Drug 
budgets became more likely to be subject to 
revision, often resulting in cuts. In addition, 
austerity has raised policymakers’ awareness of 
the need for more cost-effective policy measures. 
In some countries, reorganisation of drug 
services has been attempted. 
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Europe and those involved in analysis and research. By 
highlighting where problems might arise as a result of changes 
in financing or service provision, the report may also help 
policymakers and practitioners to minimise some of the 
negative consequences of the recession. 
The report starts by outlining its methods and approach. It 
then goes on to describe the effects that the world 2008–09 
economic contraction had on key economic and social 
variables that may affect the drug phenomenon in Europe, 
such as economic growth, unemployment and public 
expenditure. In the following section, it describes how the 
financing of national policies for health, social protection and 
public order and safety have evolved, as these areas 
encompass most drug policy spending. Assaying the available 
national data, the paper then looks at the effects of the crisis 
on drug-related public expenditure overall and by sector of 
drug policy. The final section brings together the main findings 
of the study and highlights the policy-relevant conclusions.
The analysis presented in this report is limited for a number of 
reasons: there are few available estimates of drug-related 
public expenditure, these are rarely comparable and they may 
be incomplete. As a result, this study cannot provide an overall 
estimate for European drug-related public expenditure or fully 
compare national estimates. Instead, the analysis attempts to 
draw a picture based on the information provided by EU 
Member States and augmented with information available 
from other sources. 
It should be stressed that the levels of public spending in any 
area of policy are the result of interactions between several 
factors and not only of government decisions. The most 
important factors are the level of demand for services, the 
level of public service provision decided by the government 
and the way that public services are organised, funded and 
delivered. 
I Introduction
In 2008 and the years that followed, Europe experienced a 
severe economic crisis, which presented a grave challenge to 
public finances. Many governments reacted by implementing 
stringent fiscal consolidation plans, frequently based on the 
reduction of government spending. This report examines the 
evidence to see how economic recession may have affected 
the financing of drug policy in Europe.
Consideration of public expenditure provides an 
understanding of the size and composition of the spending on 
the public programmes and interventions that frame drug 
policy and may be devoted to tackling drugs. Since the 
implementation of drug policy is funded mainly from the 
public purse, the restructuring or resizing of public budgets is 
likely to affect the quality and level of services provided. 
Analysing the evolution of public expenditure after 2008 
allows a better understanding of how the changing economic 
circumstances may have affected the financing of drug-
related initiatives. In recognition that risks to public health may 
emerge from the combination of economic contraction and 
public austerity (see the box ‘How economic crises may 
impact on drug use and interventions’), which may particularly 
affect vulnerable groups such as drug users, governments 
may prioritise actions to mitigate the impact of economic 
crises and seek to maintain broad coverage, accessibility and 
quality of essential services, despite overall budgetary 
constraints.
This report is unique in bringing together in one place the 
available data on the impact of the recession on the financing 
of drug initiatives in Europe. Hence, it is a valuable resource 
for all those who want to have a better understanding of the 
impact of this exceptional economic situation on the financing 
of interventions in the drugs field, for those involved in 
developing drug policy and responding to the drug situation in 
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The effect of an economic crisis on the drug phenomenon 
may become evident through deteriorating social 
conditions leading to changes in patterns of drug use within 
the population or through changes in service provision 
resulting from cuts in public expenditure. Fiscal austerity 
may be used as an argument to support the reorganisation 
of service provision to improve efficiency, but often the 
resultant changes are more piecemeal and may have a 
negative impact on service provision. Because of the 
multi-sectoral nature of drug interventions, the impact will 
depend on how changes in the total public finances have 
been implemented across the different sectors of public 
service provision. 
Impact on drug use
There are few analyses that focus on the impact of 
economic recession on substance use, however the 
available evidence suggests that the impact of recession 
on alcohol consumption differs according to the pattern of 
alcohol use considered: the number of moderate and 
heavy drinkers tends to rise, while the number of light 
drinkers declines (Bor et al., 2013; Harhay et al., 2013; Latif, 
2014; Richman et al., 2012). Studies have also found that 
adverse effects can be partly mitigated by providing job 
reintegration programmes and support to families during 
economic instability, as well as maintaining regulation of 
the alcohol industry (Mladovsky et al., 2012; Stuckler et al., 
2009a; Stuckler et al., 2010; Suhrcke et al., 2011). For drug 
use, the limited evidence is ambiguous (Bretteville-
Jensen, 2011). On the one hand, additional stress due to a 
less favourable economic environment, the threat of 
deteriorating labour market conditions and more 
unemployment, especially within the youth population, 
may push more people towards drug use (Arkes, 2011). On 
the other hand, a reduction in disposable income, or even 
the expectation of one, may lead to reduced spending on 
drug consumption (Costa Storti et al., 2011). Last but not 
the least, more inequality in income distribution and 
growing poverty may lead to increases in certain high-risk 
patterns of drug use, such as injection (Friedman et al., 
2009; Latif, 2014). 
Mental ill-health is strongly associated with the prevalence 
of substance use disorders (Lev-Ran et al., 2013; Nehlin et 
al., 2013; Swendsen et al., 2010). The impact of economic 
contraction on mental health has been analysed by many 
researchers (Economou et al., 2013; Gili et al., 2013; 
Katikireddi et al., 2012; Kim et al., 2003; Lee et al., 2010; 
Madianos et al., 2011; Vandoros et al., 2013; Wang et al., 
2010; World Health Organization, 2011). The comparison 
between pre-recession periods with the period that 
followed consistently shows increases in symptoms of 
psychological distress, including depression and anxiety 
disorders. According to the World Health Organization 
(2011), the 2008–09 economic contraction led to a 
deterioration in some of the factors protective of mental 
health (such as social capital, welfare protection and 
healthy workplaces), while increasing certain risk factors 
(poverty, poor education, deprivation, high debt, 
unemployment, job insecurity and stress).
Impact on health services
Whereas the evidence of the impact of recession on drug 
service provision is limited, there is a body of literature 
examining the way the health sector has been affected — 
and this is the sector where most demand reduction 
responses to drug problems in Europe are located (World 
Health Organization, 2014). Evidence from past economic 
recessions occurred during the 1980s and late 1990s 
shows that attempts by governments to maintain overall 
levels of health spending have tended to be unsuccessful, 
and governments have often failed to protect access to 
quality health services, especially for the poor (World Bank, 
2009). Indeed, in countries where public financing 
accounted for the bulk of overall health expenditure, public 
expenditure on health tended to be cut severely during 
economic recessions and for two or three years after 
(OECD, 2010b). Evidence also suggests that cuts 
disproportionally affect the more marginalised members of 
the population (Suhrcke et al., 2009; World Health 
Organization, 2013). 
Although strong social protection mechanisms can mitigate 
some of the most negative effects of recessions, austerity 
measures such as cost-cutting or increasing cost-sharing in 
health care may exacerbate the impact of economic crises 
on public health (Karanikolos et al., 2013a; Mladovsky et al., 
2012). The overall risk to public health may increase when 
economic shocks are combined with fiscal austerity and 
weak social protection.
How economic crises may impact on drug use and interventions
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funds for treating mental health, drug users will probably 
benefit (EMCDDA, 2014c; European AIDS Treatment Group, 
2014a; Kentikelenis et al., 2014). Similarly, when social 
protection policies receive more funds, governments may 
increase capacity to engage with socially excluded 
populations, including high-risk drug users (1). By the same 
token, financing law enforcement efforts against organised 
crime will have an impact on drug-law enforcement and supply 
reduction efforts (EMCDDA, 2013). 
To analyse the types of public expenditure, the European 
database on public expenditure developed by Eurostat has 
been used (Eurostat, 2014). One of the strengths of this 
database is that it provides annual data on public expenditure 
disaggregated into 10 different policy areas, according to the 
purpose of the spending. Expenditure is broken down by the 
main economic functions of government. In addition, the data 
collection is mandatory and subject to systematic control and 
validation procedures. The database is not without limitations. 
Classifying expenditure according to one out of the 10 single 
purposes can be interpreted differently by different data 
providers. And, there is still room for further harmonisation of 
definitions and accountancy practices. 
The final part of this paper reviews what is known about trends 
in drug-related expenditure. Although there has been an 
increase in the number of estimates for drug-related 
expenditure during the last decade, the quantity and quality of 
information available in Europe remain limited. When funds 
allocated by governments for expenditure on tasks related to 
drugs are identified as such in the budget they are called 
labelled expenditure. These funds can be traced back by a 
detailed review of budgetary documents, fiscal year-end 
accountancy reports, or both. In general, however, the bulk of 
drug-related expenditure is unlabelled: it is not identified but is 
embedded in broader categories of public accounts and must 
be estimated by modelling approaches. The total drug-related 
expenditure is the sum of labelled and unlabelled 
expenditures (EMCDDA, 2008). Labelled expenditure is 
frequently spread across different ministries and is found at 
many different levels of government, which may make the 
collection of data difficult. In addition, developing estimates 
for unlabelled expenditure requires considerable expertise 
and resources. As a result, the number of estimates available 
for total drug-related public expenditure at national level is 
relatively low. The amount and quality of estimates also vary 
greatly from country to country; they cover different years and 
use a range of different methodologies for estimating the 
same type of intervention in different countries. Although the 
shortage of data and inconsistencies in documentation limit 
(1)  Studies suggest that economic downturns pose clear risks to health due to 
suicides and alcohol-related deaths (Stuckler et al., 2009b; Stuckler et al., 
2010; Suhrcke et al., 2011). Policies for providing job reintegration 
programmes and support to families may partially overcome the impact of 
recession, however.
I Methods and analytical approaches
The objectives of this study are to increase the understanding 
of how European countries have changed their overall 
patterns of public expenditure after the 2008 economic 
recession and to describe trends in the components of public 
expenditure most associated with the financing of drug-
related initiatives as well as trends in drug-related expenditure 
in Europe.
With this aim, this paper incorporates a range of analyses and 
data sources (see the box ‘Data and data sources used in the 
report’). It begins with a short review of the impact of the 2008 
economic recession on key relevant economic variables and 
on public expenditure at the European level. To describe the 
economic recession in the European Union, this report 
considers its effect on a number of economic indicators: gross 
domestic product (GDP), which provides information about a 
country’s overall economic activity, measuring the total value, 
at constant prices, of final goods and services produced 
during one year; the unemployment rate, which is the 
proportion of individuals in the labour force who could not find 
a job in a certain year; and, the overall public expenditure, 
which shows the value of government acquisitions of goods 
and services within a year. 
Then, to interpret the diversity of experiences across Europe, 
principal component analysis (PCA) is used to summarise the 
variability of GDP growth, level of unemployment and growth 
of total public expenditures in 2011 (see the box ‘Measuring 
the scale of the economic recession’). Based on these 
variables, countries were ranked and, subsequently, divided 
into four groups containing an identical number of countries.
Public expenditure on public order and safety, health and 
social protection are examined here, as these are the areas 
where most drug-related activities and services are provided. 
In the absence of comprehensive and comparable time series 
of estimates for drug-related public expenditure, such an 
analysis may provide some insight into the likely trends in 
drug-related expenditure in different countries. The findings 
from this approach, however, must be viewed with caution, as 
the proportion of drug-related expenditure in each of these 
categories is quite small. In 2005, for example, drug-related 
initiatives accounted for between 2 % and 12 % of public 
expenditure on public order and safety and not more than 
1 % of public expenditure on health and social protection 
(EMCDDA, 2008). Therefore, the possibility must be 
considered that drug-related expenditure has been affected 
by austerity in a different way to the overall pattern, either 
being relatively protected or harder hit. 
Nevertheless, changes in expenditure within these broad 
categories are likely to impact on the provision of drug-related 
services. For example, when a hospital allocates or uses more 
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The financial crisis soon led to a broader economic crisis. 
According to the European Commission (2013a), the financial 
crisis that hit the global economy in the summer of 2007 has 
no precedent in post-war economic history. It differed from 
other economic fluctuations in its magnitude and the degree 
to which it was synchronous around the world. In 2009, the 
world economy contracted, having an overall GDP growth rate 
of −0.4 %, while the EU27 rate was −4.3 % (Figure 1). In 2012, 
the EU27 registered another, less pronounced, recession, but 
emerging data indicate that the economic outlook for the 
European Union has strengthened since 2013 (European 
Commission, 2014).
FIGURE 1
Real GDP growth rate in the world and the EU27, 2000–2012
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Source: (International Monetary Fund, 2013b)
the scope for cross-country comparisons, they do not prohibit 
an analysis of time trends in drug-related expenditure in 
individual countries. 
It is important to note that estimates of public expenditure can 
reveal only the amount of monetary resources allocated to a 
policy area. Expenditure estimates provide no information 
about any of the aspects of service provision, such as quality 
or coverage. In this report, therefore, questions about the 
impact of austerity on the cost-effectiveness of services are 
not addressed.
I Impact on public spending
According to the US government’s Financial Crisis Inquiry 
Commission, in September 2007, the collapse of the US 
housing bubble — fuelled by low interest rates, easy and 
available credit, scant regulation and toxic mortgages — 
initiated a string of events which led to a full-blown crisis in 
the autumn of 2008. Vast sums of money in risky mortgages 
had become embedded throughout the financial system, as 
mortgage-related securities were packaged and repackaged 
and sold around the world. When this bubble burst, vast 
losses hit markets and financial institutions around the world. 
This crisis reached systemic proportions in 2008, jeopardising 
the world financial system (Financial Crisis Inquiry 
Commission, 2011).
This analysis of the economic recession and its impact on 
drug policy draws on three main types of data. 
The information on drug-related public expenditure used in 
this report is based on quantitative and qualitative data 
provided by the Reitox national focal points between 2006 
to 2013, except where stated otherwise when reliable 
estimates are available from other sources. The EMCDDA 
collects data from the 28 Member States of the European 
Union as well as from Norway and Turkey, primarily through 
annual national reports on the drug situation. For this 
report, additional information was collected in a targeted 
data collection undertaken in 2011/12 (Reitox national focal 
points, 2013). The analysis presented here refers to the 27 
EU Member States as of 2012 (EU27). 
This paper also draws on a study commissioned by the 
EMCCDA (1), which explores the potential impact of the 
recession by reviewing Eurostat data on overall public 
expenditure. Based on the international Classification of the 
Functions of Government (COFOG) (Eurostat, 2014), this 
study analysed the three primary sectors where drug-
related activities and services are provided (EMCDDA, 
2008). These sectors are public order and safety, which 
includes expenditure on police services, law courts and 
prisons; health, which contains, for instance, expenditure on 
medical products, outpatient services and hospital 
services; and social protection, which includes expenditure 
in areas such as sickness and disability, unemployment and 
social exclusion. 
In addition, whenever possible, the analysis is 
complemented with literature available, as well as relevant 
analysis made by other international organisations. 
(1)  This report is based on the results of a study undertaken for the EMCDDA 
by Olivera (2013).
Data and data sources used in the report
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reducing government deficits and debt accumulation — had a 
concrete impact, with EU27 budget deficits shrinking markedly 
between 2009 and 2012. As can be seen in Figure 4, fiscal 
consolidation has been primarily pursued by reducing 
expenditure rather than increasing revenue, although the 
balance varies considerably between countries.
Although estimates for 2014 show that many European 
countries intended to reduce their budget deficit, there is a 
debate within the countries about the best way to respond to 
the changing economic circumstances. Concerns have been 
raised that further fiscal consolidation amid weak growth 
prospects may have detrimental effects on growth in the short 
term (European Commission, 2012). Nevertheless, this seems 
likely to continue to be the dominant approach (European 
Commission, 2013b).
In 2008 and 2009, public expenditure as a percentage of GDP 
increased sharply, but temporarily, in the EU27 (Figure 3). Part 
of the increase is explained by the fall of GDP and part by the 
increase of public expenditure aimed at strengthening the 
financial system, stimulating the economy and in responses to 
the crisis, such as increases in unemployment benefits 
(OECD, 2011). After 2009, total public expenditure started to 
decline. The evolution of public expenditure varied markedly 
from country to country (see Tables A3 and A4).
During the crisis, the fortunes of countries were 
heterogeneous. Olivera (2013) analysed the impact of the crisis 
in the EU27 and Norway. The Baltic States were the countries 
most severely hit by the crisis in 2009, with GDP contracting by 
between 14.1 % and 17.7 %. Other countries badly affected 
were Hungary, Romania, Slovenia and Finland, where the 
decline in GDP ranged from 6.6 % to 8.5 %. In Bulgaria, the 
Czech Republic, Denmark, Germany, Ireland, Italy, Slovakia and 
Sweden, GDP fell by between 4.5 % and 5.7 % (Table A1).
This economic crisis had severe social consequences. 
Unemployment increased substantially (Figure 2), rising from 
7.1 % of the EU27 labour force in 2008 to 10.5 % in 2012. 
According to the International Monetary Fund (2011), the 
recession will have lasting consequences in the labour 
markets, even in those countries with government-supported 
work programmes or in countries with strong social safety nets 
cushioning the blow to households. Youth unemployment 
registered an exceptional increase during the crisis, rising to 
over one-fifth of the young working population, and continued 
to grow in the years that followed (Figure 2). Again, the impact 
of the crisis varied markedly between countries (Olivera, 2013).
Another legacy of the recession was the increasing public 
deficits in many European countries, raising the public deficit 
from 0.9 % of EU27 GDP in 2007 to a peak of 6.9 % in 2009 
(Figure 3). This occurred, first, because the contraction in 
domestic demand reduced tax revenues and, secondly, because 
governments supported the financial sector and sometimes 
parts of the non-financial corporate sector. Government 
expenditure increased also, for instance, due to the payment of 
unemployment benefits, which is accounted as public 
expenditure on social protection. As a consequence, European 
countries like Ireland, Greece, Cyprus, Latvia, Hungary, Portugal 
and Romania required financial assistance from the European 
Union. Countries like Belgium, Czech Republic, Italy, Poland, 
Slovenia, Slovakia and the United Kingdom also introduced large 
fiscal consolidation plans (OECD, 2012c). These fiscal 
consolidation programmes — specific policies aimed at 
FIGURE 2
Unemployment rate in the EU27, 2000–12
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FIGURE 3
Public deficit and public expenditure in the EU27 as a 
percentage of GDP, 2000–12
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is a measure of the reduction in public expenditure as a 
percentage of the GDP, in accumulated terms, between 2009 
and 2011. During that period, the countries that experienced 
greater levels of austerity tended to show greater reductions in 
expenditure in the three sectors that cover most drug-related 
activities. However, the effects of austerity on the areas of 
public spending were more marked on health and public order 
and safety and less so on social protection (Figure 5).
FIGURE 5
Linear relationship between the cumulative growth of public 
expenditure in real terms, by function, and austerity
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Source: IMF, Fiscal monitor database, April 2013, Statistical Table-T2
Greece, Spain, France, Italy, Netherlands, Austria, Portugal, Slovenia, Slovakia, 
Sweden, Finland, United Kingdom) and Norway. In this analysis, the level of 
public austerity is measured by the accumulated increase of the cyclically 
adjusted public deficit (or negative balance) in the period between 2009 and 
2011. The higher the increase in this budget deficit, the higher the level of 
austerity implemented in a country. 
FIGURE 4
Expenditure-based versus revenue-based measures in fiscal 
consolidation plans (2009–15)
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I  Impact on overall expenditure covering drug-related activities
Public expenditure on those areas encompassing most drug-
related initiatives has been affected by the changing economic 
circumstances, but this impact has differed both across 
countries and across sectors. After 2008/09, expenditure on 
public order and safety, health and social protection, as 
reported in the IMF Fiscal Monitor Database, have all changed, 
but to different extents (Figure 5). The level of public austerity (2) 
(2)  The IMF uses the change in the general government cyclically adjusted 
balance, as a percentage of the potential GDP, to measure national public 
austerity (International Monetary Fund, 2013a). The IMF provides information 
for 17 EU countries (Belgium, Czech Republic, Denmark, Germany, Ireland, 
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The increase in private contributions has been substantial in 
countries such as Bulgaria, Ireland and Slovakia. In other 
countries, it has been less marked (OECD, 2012b). For 
instance, in 2011, 13 countries showed a reduction in public 
health expenditure, in real terms. Only nine countries recorded 
real growth in public health expenditure in each of the three 
years from 2009 to 2011 — Belgium, the Czech Republic, 
Germany, France, Cyprus, Netherlands, Finland, Sweden and 
Norway — but in general, this was at a markedly lower rate 
than in previous years.
FIGURE 6
Public expenditure on health in the EU27 
top: as a share of total public expenditure; centre: as a share 
of GDP and; bottom: annual real growth rate
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I Health spending
The public sector is the main source of financing for health care 
in Europe. This is the area where governments pay, for example, 
for medicine for drug-treatment, outpatient drug treatment or 
hospital services provided to drug users. Overall, health 
insurance coverage is universal or almost universal in all EU 
Member States through compulsory health insurance or 
national or local health service provision (European Commission 
and Economic Policy Committee, 2010). The contribution of 
public expenditure to total health expenditure was 77 % in the 
EU27 in 2008 (OECD, 2010a). In general, private health 
insurance accounts for a small but growing proportion of total 
health expenditure, while the proportion of total health 
expenditure financed by out-of-pocket payments has been 
relatively low in the EU27 (14 % in 2008) (OECD, 2010a). 
However, the economic recession has affected this picture.
In the years leading up to the financial crisis, health spending 
accounted for a significant and growing proportion of the GDP 
and public expenditure of the EU27 (Figure 6), and the health 
sector grew at a faster rate than other areas of the economy. 
This was driven by factors such as changing demographics, in 
particular an ageing population, in addition to sometimes 
costly technological developments. In some countries, new 
requirements for increased accountability among medical 
staff may also have resulted in doctors using expensive 
so-called ‘defensive medicine’ (Oliveira Martins and 
Maisonneuve, 2006; World Health Organization, 2014). 
However, in 2010, notwithstanding these structural factors, 
the consequences of the economic recession were that public 
expenditure on health started declining (Figure 6; Table A5). 
Between 2000 and 2008, average public expenditure on health 
increased annually by 3.4 % in the EU27, after discounting for 
inflation. In 2009, the year of acute economic contraction, this 
expenditure increased by 5.0 %. However, after that it declined 
(by 0.1 % and 1.0 %, in 2010 and 2011, respectively).
The economic crisis has also affected the mix of public and 
private health financing in Europe. Between 2008 and 2010, 
the public-sector share of total health expenditure declined 
from 77 % to 73 % (OECD, 2010a). Public spending on health 
has been cut for certain goods and services, often combined 
with increases in the share of direct payments by households. 
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Countries have dealt with the trade-off between their need for 
additional social protection in periods of economic crisis and 
their need for public austerity in different ways. For instance, 
in 2009, only 1 out of 28 countries — EU27 and Norway — 
reduced expenditure on social protection in real terms; 7 
countries did so in 2010, and 17 in 2011 (Table A6). However, 
11 countries demonstrated some level of real growth in 
expenditure in each of the three years (Belgium, Czech 
Republic, Ireland, France, Cyprus, Luxembourg, Malta, 
Netherlands, Slovenia, Finland and Norway), although 
generally at declining levels in 2010 and 2011.
I Social protection spending
Public expenditure funds a system of welfare payments that 
offer social protection against a set of defined needs and risks 
such as illness and disability, old age, family and children, 
unemployment, housing and social exclusion. This is the area 
where governments may provide cash benefits or benefits in 
kind to citizens who are socially excluded, including those with 
drug and alcohol problems. 
In the early 2000s, expenditure on social protection 
accounted for almost 18 % of EU27 GDP. In 2009, public 
expenditure in this area increased as a proportion of GDP, 
partly because expenditure grew in real terms and partly 
because GDP fell (Table A1 and Table A6). The increase also 
reflected the greater need for social support, namely for 
unemployment benefits. However, this trend reversed after 
2009. In 2010, the increase in expenditure on social protection 
was very modest, despite the continued growth observed in 
unemployment. The higher expenses caused by the greater 
number receiving unemployment benefits were partially 
compensated for by a decline in the average benefits for the 
unemployed. Additionally, public expenditure on sickness and 
disability, old age, family and social exclusion and housing 
declined markedly (European Commission, 2013c; OECD, 
2012d). In 2011, the decline continued and affected most 
EU27 countries, leading to a decline in expenditure in real 
terms. In the EU27, social protection expenditure grew by 
6.7 % in 2009, 1.0 % in 2010 and fell by 0.7 % in 2011 
(Table A6). The European Commission concluded that, until 
2009, social spending played a prominent role in 
compensating households’ income losses and helping to 
stabilise the economy. However, this has been weakening 
since 2010 (European Commission, 2013c).
The reduction in social spending seen in 2011 has been much 
stronger than in past periods of below-par economic 
performance, partly reflecting the exceptional need for fiscal 
consolidation in the context of the euro crisis (European 
Commission, 2013b). Social protection policies impacted 
differently on high and low income households, depending on 
the design of measures and, in some countries, the poorest 
were the most affected (European Commission, 2013c).
FIGURE 7
Public expenditure on social protection in the EU27
top: as a share of total public expenditure; centre: as a share 
of GDP and; bottom: annual real growth rate 
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I Spending on public order and safety
Expenditure on public order and safety encompasses the 
financing of most drug supply reduction initiatives, including 
most drug-related interventions performed by police, law 
courts and prison services. These services are mainly 
provided by the public sector in Europe, and on average, this 
expenditure represented only between 1.8 % and 2.0 % of 
EU27 GDP between 2002 and 2011. However, within this 
period there was positive yearly real growth until 2009, after 
which growth decelerated in 2010 and became negative in 
2011. Again, the impact of recession differed markedly across 
countries. In 2009, out of 28 countries, only 6 showed a real 
decrease in expenditure on public order and safety. In 2010, 
13 countries experienced a fall in this expenditure in real 
terms. In 2011, 17 countries experienced a decline and the 
real decrease in public order and safety expenditure was most 
marked in Greece (12.7 %), Czech Republic (9.7 %), Slovenia 
(7.6 %), Romania (6.3 %) and Cyprus (6 %), while the Baltic 
States, which had reduced expenditure dramatically in 2009 
(by between 17.9 % and 27.4 %), stabilised spending. Only five 
countries — Germany, France, Luxembourg, Sweden and 
Norway — increased spending on public order and safety in 
real terms in all three years from 2009 to 2011, although often 
only by small amounts (Table A7).
FIGURE 8
Public expenditure on order and safety in the EU27 
top: as a share of total public expenditure; centre: as a share 
of GDP and; bottom: annual real growth rate 
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The impact of the economic recession registered in each 
country was ordered based on principal component 
analysis (PCA) (see Hatcher, 1994; Olivera, 2013). This 
method takes into account a selected set of information 
and summarises it in an index (1). In this case, the index 
aims to order countries according to the severity of the 
impact of the economic recession. To categorise the impact 
of national economic recessions, three types of variables 
were used in the PCA:
n  real growth of GDP, to measure the overall economic 
performance of a country;
n  total unemployment and unemployment of young people 
as indicators of the social impact of the crisis; and 
n  real growth of total public expenditure as an indicator of 
austerity in the public sector. 
First, the variance of these variables is calculated for each 
country, which subsequently allows the countries to be 
ranked in an index, according to the impact of the economic 
recession: from the country least affected to the country 
most affected by the economic recession. 
As a final step, countries are divided into four groups with 
an identical number of countries per group.
The grouping of countries (see the table) can be roughly 
described as follows:
Group 1. Low impact. These countries had, on average, the 
highest GDP per capita (at constant prices) in 2011 and 
suffered the least in this economic recession, generally 
maintaining relatively stable growth in public expenditure 
and comparatively low rates of unemployment, while GDP 
growth dipped only briefly before bouncing back.
Group 2. Moderate impact, early recovery. This group had, 
on average, the second highest level of GDP per capita in 
2011, although there was marked variability in per capita 
GDP between the countries in the group. Nevertheless, they 
appear to have reacted similarly to the crisis. Recession hit 
Group 2 markedly in 2009 but recovery was already 
apparent in 2010. Governments introduced austerity early 
and, in 2010, total public spending diminished in real terms, 
which was immediately reversed in 2011, resulting in 
positive growth of total public expenditure in 2011.
Group 3. Moderate, more sustained impact. Generally, this 
group has slightly less favourable economic indicators 
than the previous group, in particular higher 
unemployment rates.
Group 4. High impact. This group includes those countries 
most severely hit by the 2008 economic recession in 2011. 
In 2009, on average, the GDP of these countries fell by 
close to 7 % (real terms) and, in the two years that followed, 
recovery was the weakest of all the groups. In particular, 
unemployment grew rapidly and by 2011 was at extremely 
high levels: youth unemployment was on average 35.2 %, 
while total unemployment was 16 %. Overall, public 
expenditure also decreased dramatically in 2011.
Measuring the impact of the economic recession
European countries grouped according to impact of the recession
Group
GDP growth 
rate 
(constant 
prices, %) 2011
Public 
expenditure 
growth 
(constant 
prices, %) 2011 
Total 
unemployment 
rate 
2011
Youth 
unemployment 
rate 
 2011
GDP per capita 
(constant 
prices) 
2011 
EU(27)=100
1 Germany, Luxembourg, Malta, 
Netherlands, Austria, Sweden, Norway
2.1 0.1 5.3 12.3 178.2
2 Belgium, Czech Republic, Denmark, 
Estonia, Romania, Slovenia, Finland
2.7 0.5 8.2 18.9 92.4
3 Bulgaria, France, Italy, Cyprus, Hungary, 
Poland, United Kingdom
1.7 −1.0 9.4 24.6 74.2
4 Ireland, Greece, Spain, Latvia, Lithuania, 
Portugal, Slovakia
1.1 −7.7 16.0 35.2 71.0
Total EU27 and Norway 1.9 −0.8 9.7 22.8
NB: Based on a PCA of selected indicators.
Source: Olivera (2013) and Eurostat
(1)  For example, it is common practice to use the PCA to create an index of 
living standards with the information of different variables available in a 
household survey. PCA enables different information from individuals 
(countries in this case) to be aggregated into a summary measure, which 
can explain the maximum amount of observed variability. For more 
information, see Olivera (2013) and Hatcher (1994).
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I Variation in public expenditure growth
Before the recession, the components of public expenditure 
that encompass most drug-related activities were, on average, 
increasing in each of the four country groups, but less so in 
the group least affected by the downturn (Group 1). After 
2008–09, when austerity programmes were implemented 
across Europe, these expenditures continued to grow in Group 
1 countries, but at a slower pace than before. This contrasts 
with what is observed in the other three groups, where 
expenditure frequently declined after 2009.
In the countries most affected by recession (Group 4), the 
pattern of growth of public expenditure that encompasses 
most drug-related activities changed markedly. Between 2000 
and 2007, expenditure grew faster on average in Group 4 than 
in the other groups, but following the recession, the biggest 
falls in expenditure occurred in this group. Health expenditure 
was particularly hit, declining in real terms by 7.0 % in 2010 
and 4.6 % in 2011, on average. Expenditure on social 
protection also fell markedly, especially taking into account 
the increase observed in unemployment. Public order and 
safety expenditure managed to maintain a very modest real 
growth rate (0.4 %) in 2010, which was not sustained in 2011 
(−3.3 %).
The literature provides a variety of explanations for the 
vulnerability of health financing to cuts (Mladovsky et al., 
2012). For instance, the increasing costs of public health 
systems occurred in the previous decade have exposed this 
sector to a negative public opinion; the reports of 
inefficiencies of health systems may have made it politically 
difficult to argue for maintaining previous levels of spending; 
health spending may be easier to cut than other areas, such as 
social protection, which would be normally pushed upwards 
by unemployment subsidies paid as a consequence of rising 
unemployment levels; and because health benefits are less 
clearly defined and less obvious to the public than social 
protection benefits. The need to be aware of the potential 
impact of such cuts to health sector spending have been 
highlighted in an OECD (2012b) analysis which concludes 
that, ‘some measures may have an impact on the 
fundamental goals of the health systems. Continuous 
monitoring of data and indicators on health and health 
systems is therefore important; it provides indications of the 
potential short and longer-term impact of the changing 
economic circumstances and health policies on health care 
access, quality and health outcomes.’
Before 2007, European countries showed strong positive 
growth in their annual expenditure on social protection; the 
situation changed after the crisis. Table 1 shows that while in 
2010, only high impact countries (Group 4) showed real cuts 
in their annual financing of social protection, in 2011, when 
unemployment escalated in most European countries, real 
I  Variation in impact between countries and sectors
As described above, the extent of the recession, the response 
to it and the timing of these varied markedly between 
countries in the EU (3). To understand these different 
experiences, Olivera (2013) used a statistical technique called 
principal component analysis (PCA) to group countries into 
four equally sized groups based on their level of GDP growth, 
overall unemployment rate, youth unemployment rate and 
growth in public expenditure in 2011 (see the box ‘Measuring 
the scale of the economic recession’). While the decision to 
form four equal groupings is arbitrary, and a PCA using 
different years or different variables would group countries 
differently, comparison between these groups provides an 
illustration of the range of experiences within Europe. 
Although there are limited data available to assess the impact 
of recession and associated austerity on drug policy, some 
indication can be obtained by considering changes in public 
expenditure in those sectors that include most drug-related 
activities and by looking at the reported experiences of those 
countries that have provided more detailed information. 
Patterns of growth in public expenditure differed between the 
four country groups (Table 1).
TABLE 1
Average growth (%) of public expenditure (constant prices) 
for health, social protection and public order and safety 
across the four country groups before and after the recession
Group 1 Group 2 Group 3 Group 4
EU27 and 
Norway
Health
2000–2007 4.0 4.8 4.5 8.0 5.6
2010 1.7 −0.9 1.1 −7.0 −1.4
2011 1.6 0.3 −0.3 −4.6 −0.8
Social protection
2000–2007 2.2 3.7 3.7 3.9 3.9
2010 1.7 0.3 2.1 −1.1 0.7
2011 0.7 −0.6 −0.2 −2.3 −0.6
Public order and safety
2000–2007 2.4 5.1 4.4 6.7 4.7
2010 1.8 2.4 0.5 0.4 1.3
2011 1.4 −2.5 −1.8 −3.3 −1.5
Note: Group 1: Germany, Luxembourg, Malta, Netherlands, Austria, Sweden, 
Norway. Group 2: Belgium, Czech Republic, Denmark, Estonia, Romania, 
Slovenia, Finland. Group 3: Bulgaria, France, Italy, Cyprus, Hungary, Poland, 
United Kingdom. Group 4: Ireland, Greece, Spain, Latvia, Lithuania, Portugal, 
Slovakia.
(3) Country data used for the analysis are presented in the Appendix.
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complete picture for Europe to be drawn, the focus here will 
be on examples of what was observed in some countries and 
in some sectors of drug policy. 
I Overall trends in drug-related expenditure
The available quantitative and qualitative data on drug-related 
expenditure suggest that drug-related spending in many 
countries has either stagnated or declined following the 
economic crisis of 2008. However, the extent of the 
moderation in spending differed substantially from country to 
country, as has been described above in relation to overall 
public expenditure on those areas encompassing most 
drug-related initiatives. The available information seems to 
suggest that the greater the impact of the recession on a 
country’s economic variables, the more severe was the impact 
of austerity on the financing of drug-related initiatives. 
Even in the countries where the impact of the crisis was low 
(Group 1), there are indications that drug policy may have 
been affected by austerity (4). In Luxembourg, for example, a 
cut in total drug-related expenditure, implemented in 2009, 
mainly affected unlabelled expenditure. Nevertheless, 
estimates for labelled drug-related expenditure show that the 
funding of some drug initiatives (such as types of health 
interventions) was either spared or even increased, after 
discounting for inflation. Data for the years after 2009 suggest 
that drug-related expenditure has started to increase again. 
Thus, the impact of recession on drug-related expenditure was 
visible in Luxembourg, but seems to have been circumscribed 
in time and affected some sectors only. Information about 
German drug-related expenditure also seems to show a 
limited impact. In Germany, partial data for treatment seem to 
indicate that some drug initiatives were subject to capped 
budgets as a consequence of some austerity. 
Countries in Groups 2 and 3 (5) are analysed together because 
their trends in drug-related expenditure cannot be clearly 
distinguished. Bearing in mind the limited data, the available 
information seems to suggest that drug-related expenditure 
either stagnated or diminished in real terms in many of these 
countries.
(4)  Four out of the seven countries in this group have provided data on total 
annual drug-related public expenditure at least once in the last decade. A 
complete analysis of the recent evolution of total drug-related public 
expenditure exists only for one country, and a sectoral analysis was made for 
another one. Bearing in mind the data limitations, total drug-related public 
expenditure is estimated to have represented between 0.1 % and 0.5 % of 
GDP in these countries. 
(5)  In these groups, three countries have provided regular estimates for total 
drug-related public expenditure covering the period before and after 2008, 
and three others estimate labelled expenditure regularly. Taking note of the 
lack of comparability across countries, total drug-related expenditure 
represented between 0.03 % and 0.11 % of national GDP in Group 2 countries; 
and between 0.08 % and 0.48 % of national GDP in Group 3 countries. 
cuts in expenditure on social protection were experienced in 
other two country groups. From an analysis of public 
expenditure on social protection, the European Commission 
(2013c) concludes that, ‘while social spending played a 
prominent role in compensating households’ income losses in 
the early phase of the crisis (until 2009), and helped stabilise 
the economy, this impact has been weakening since 2010. 
After an initial increase in the first year of the crisis, social 
expenditure levelled off in 2010 and declined in 2011 and 
2012, sometimes in countries where unemployment kept 
rising. This reduction of social spending was much stronger 
than in past periods of below-par performance partly 
reflecting the exceptional need for fiscal consolidation in the 
context of the euro crisis. It neutralised the economic 
stabilisation function of social protection systems in many 
Member States.’
Expenditure on public order and safety was also affected by 
the recession, although to a lesser extent and slightly later 
than occurred for health expenditure. After 2008, expenditure 
on public order and safety maintained relatively stable growth 
rates only in those countries where recession had a low 
impact (Group 1). Otherwise, after some moderation in 2010, 
2011 was a year when most countries registered cuts in real 
spending. 
I Impact on drug-related public expenditure 
National information for total drug-related public expenditure 
covering the period before and after the economic recession 
is limited in Europe, and most of the countries provide 
estimates until 2011 only, when the impact of austerity was 
still not complete. Furthermore, the number of countries with 
estimates of trends is small. Therefore, this report will only 
present some preliminary indicative findings. Further data 
would be necessary to confirm these and to analyse how the 
provision of drug services has been affected. 
Bearing in mind these limitations, this section will analyse, 
first, the existing information for recent changes in total 
drug-related expenditure. Secondly, it will focus on the sectors 
most affected by the changing economic environment. Finally, 
it will present the protective strategies used by some 
countries in their efforts to minimise the potential negative 
impact of austerity. 
Estimates for trends in total drug-related public expenditure, 
covering the period before and after 2008, are available for six 
countries only. Partial information exists for a further six 
countries. It is not possible to compare estimates between 
countries, as different estimation methods are used and 
estimates cover different proportions of the total drug policy 
budgets. As the available information does not allow a 
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In the last decade, 16 European countries have provided 
comprehensive estimates of drug-related public 
expenditure (1). These countries report expenditure 
estimates ranging from 0.01 % to 0.5 % of GDP (see 
EMCDDA, 2014b). Reports have also estimated the 
allocation of funds for different types of drug-related 
initiatives, but special caution is required when making 
comparisons between countries, as studies may not apply 
the same classification of expenditure or the same methods 
to make estimates. The two major types of drug-related 
initiatives are supply reduction and demand reduction 
interventions. Financing of some transversal initiatives is 
also reported, but these normally involve a small proportion 
of the total and cover coordination, education and research.
The limited data available suggest that drug supply 
reduction activities account for the largest share of 
drug-related public expenditure in most countries. Public 
expenditure on supply reduction initiatives would include 
drug-related expenditure on police services, law courts and 
prisons, and this activity would all be classified within the 
Classification of the Functions of Government (COFOG) 
category public order and safety. Out of the 16 countries 
presenting complete estimates of drug-related public 
expenditure, only four countries spent less than 50 % of 
their total drug-related expenditure on supply reduction, 
while five countries spent 70 % or more. The other 
countries spent between 50 % and 70 % of drug-related 
expenditure on supply reduction (EMCDDA, 2014c). 
Nevertheless, funds allocated to drug-related initiatives 
account for only a small proportion of the overall public 
expenditure on public order and safety. In this group of 16 
countries, drug supply reduction represented between 1 % 
and 20 % of the expenditure on public order and safety, 
whereas an earlier study by the EMCDDA (2008) estimated 
that, in 2005, such supply reduction expenditure 
represented between 2 % and 12 % of total public 
expenditure on public order and safety. 
(1)  Belgium, Czech Republic, Germany, France, Croatia, Italy, Cyprus, Latvia, 
Luxembourg, Hungary, Netherlands, Portugal, Slovakia, Finland, Sweden 
and United kingdom. Additional information about drug-related 
expenditure for each country is available at http://www.emcdda.europa.
eu/topics/drug-related-public-expenditure.
Attempts to estimate public expenditure on demand 
reduction initiatives alone have been more frequent, but the 
sub-categories used to classify activities varied 
considerably in Europe. Some researchers utilise the 
sub-categories of prevention, treatment and harm 
reduction, while others categorise most activities in these 
areas under the broad heading of health. Some researchers 
identify expenditure on social protection or reintegration 
initiatives. Whereas health accounts for about 30 % or more 
of the total drug-related expenditure reported for Belgium, 
France and Luxembourg, spending on social protection was 
reported by six countries (Croatia, Latvia, Luxembourg, 
Slovenia, Finland, United Kingdom), where it represented 
between 0.8 % and 22.5 % of total drug-related expenditure. 
The EMCDDA (2008) estimated that, in 2005, drug-related 
health and social protection interventions accounted for 
less than 1 % of the public expenditure on health and social 
protection in Europe.
One of the possible explanations for a higher frequency of 
estimates for public expenditure on demand reduction 
initiatives (especially on health) than for supply reduction is 
related to accountancy practices and the way governments 
elaborate drug-related health budgets. Drug-related health 
expenditure, such as that for drug treatment services, is 
often identified as such in the budget — it is ‘labelled’. In 
contrast, most supply reduction activity is conducted as 
part of routine police, court or prison service activity, and 
the expenditure related to these activities is not separately 
identified. Since drug-related health expenditures are often 
better identified in public accountancy, they may be easier 
to spot and, therefore, to incorporate in estimates for 
drug-related expenditure. In a study by the EMCDDA 
(2008), 67 % of the labelled drug-related expenditure 
identified was spent on health and 22 % on public order and 
safety. The remaining labelled expenditure was classed as 
general public services, defence, economic affairs, housing 
and community amenities, education, and social protection. 
Hence, although drug-related public order and safety makes 
up a higher proportion of overall drug-related public 
expenditure estimates than health functions, drug-related 
health expenditure is more often identified as such in 
accountancy documents.
Overview of drug-related public expenditure data in Europe
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information suggests that most of these countries observed 
cuts in expenditure in several drug-related initiatives in the 
years that followed 2008. These are discussed below. 
A different type of impact that can be identified after 2008, 
which was common to many countries in all groups, was that 
the amount of funds policymakers and public managers could 
expect to have available became more difficult to forecast. 
Alongside this, the funds effectively available varied 
substantially from one year to the next, as the volatility of 
public funds available for drug initiatives increased after 2008. 
As a result, it became more difficult to organise and plan drug 
initiatives. The negative consequences of this for the health 
sector were highlighted by the World Health Organization 
(2013), which stressed the need to guarantee that health 
systems can plan their future funds, because sudden 
interruptions to public funding streams may hamper the 
maintenance of necessary levels of health care. 
I Impact on different sectors of drug policy
As described earlier, the data on trends in public expenditure 
in those sectors that cover most drug-related initiatives 
suggested that the impact of the 2008 recession differed 
between sectors and that the impact of austerity on 
expenditure in the health sector was greatest.
Demand reduction expenditure
Overall, the available information suggests that the impact of 
the 2008 recession on the financing of drug-related health 
interventions varied markedly from country to country. Many 
countries mentioned that spending on drug-related treatment 
and social rehabilitation was negatively affected by the 
economic crisis. The impact of austerity appears to have been 
more marked in those countries where the crisis hit more 
severely, as would be expected. In addition, a number of 
countries report having made adjustments in the financing of 
different types of drug treatment, particularly with respect to 
the balance between more expensive residential and cheaper 
outpatient treatment, as well as some other effects of 
expenditure cuts. 
Luxembourg and Germany provide examples of the impact in 
the group of countries (Group 1) identified as least affected by 
the recession. In Luxembourg, between 2009 and 2011, 
labelled drug-related expenditure on health increased by 10 %, 
in real terms, and expenditure was directed to the following 
areas or aims: primary prevention, low-threshold services, 
increased coverage of post-therapeutic services, further 
decentralisation of ambulatory treatment, and improved 
technical control of substitution treatment. Conversely, in 
Germany, although drug treatment data suggest that treatment 
The Czech Republic is an example of a country where the 
growth of total drug-related expenditure seems to have 
decelerated temporarily after 2008, and may have fallen in 
2011. In 2008, when the crisis had still not fully impacted in 
the Czech Republic, total drug-related public expenditure 
increased by 14.4 %, in real terms. In 2009, growth in 
expenditure slowed markedly but increased again in 2010 
(1.9 % and 6.7 %, respectively). Partial information for 2011 
suggests that drug-related expenditure fell, reflecting the 
national concerns with fiscal austerity (6). In France, a similar 
deceleration of drug-related public expenditure was visible, 
but not until after 2009. In 2009, total drug-related public 
expenditure grew by 14 %, but in 2010, it decelerated to 1 %, 
in real terms. In Finland, between 2006 and 2008, total 
drug-related public expenditure grew steadily, at close to 
4.5 % a year, in real terms. In 2009, it declined by 0.4 % only (7). 
In Slovenia, comparable data show that drug-related public 
expenditure grew in 2008 (4.6 %), declined in 2010 (6.3 %), 
and recovered strongly in 2011 (12.6 %) in real terms. In 
Estonia, estimates seem to show that real cuts were made in 
total funds allocated to drug-related initiatives in 2009 and 
2010, which contrast with the growth estimated for 2007, 
2008 and 2011. Data for the United Kingdom are partial, as 
trend data cover labelled expenditure only for the period 
2005–10. However, the available data suggest that labelled 
expenditure was stable between 2005 and 2007, but declined 
in 2010 as a percentage of GDP — the last year with estimates.
In Group 4, those countries worst hit by the recession, data for 
trends in drug-related expenditure are particularly limited (8). 
Trend analysis of labelled expenditure is only possible for one 
country. In Ireland, labelled expenditure increased between 
2005 and 2008. However, the trend reversed after 2008, 
probably as a result of the public austerity measures that 
followed the economic recession. In 2009, the need to achieve 
a ‘prudent fiscal outturn’ led to an attempt to cut labelled 
drug-related expenditure across all government bodies, and in 
2010 and 2011, labelled drug-related public expenditure 
diminished by 1.8 % and 7.8 %, respectively. In 2012, some 
additional cuts were observed.
In other countries from Group 4, information is partial and 
concerns mostly health expenditure. However, the available 
(6)  In 2011, estimates concern drug-related labelled expenditure only, as 
compared to the total (labelled and unlabelled expenditure) available for the 
previous years. Information reported by the national focal point was 
complemented by data provided by Valprovil and Rossi (2013).
(7)  Data for total expenditure in 2010 is not fully comparable with 2009, due to a 
change in estimation method.
(8)  In Group 4, two countries provided estimates for total drug-related public 
expenditure and three others provided estimates for labelled expenditure. 
Taking note of the lack of comparable estimates, the latest estimates may 
suggest that total drug-related expenditure represented approximately 
between 0.03 % and 0.05 % of national GDP and estimates for countries with 
labelled expenditure vary between 0.02 % and 0.16 % of GDP. However, 
relatively complete trends are available for one country and for labelled 
expenditure only.
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Many high-impact countries (Group 4) reported that austerity 
hit their health services. In Greece, in 2010 and 2011, 
notwithstanding the government’s vigorous reaction to an HIV 
outbreak, which probably prevented further cuts in some 
drug-related health initiatives, the available evidence suggests 
that there was a marked decline in overall funding of drug-
related programmes (Karanikolos et al., 2013b; Kentikelenis et 
al., 2014; Malliori et al., 2013; Reitox national focal points, 
2013). Indeed, despite the Greek government increasing the 
number of opioid substitution treatment units after 2010, this 
was attained at the expenses of cuts in the wages of civil 
servants, among other measures. Those budgets of the main 
institutions providing drug treatment show marked declines, 
and most drug-related initiatives, such as syringe and condom 
provision, had less domestic funding available, which was only 
partly compensated by more international funding to harm-
reduction initiatives (9). 
In Latvia, budgets for inpatient drug treatment were reallocated 
in order to privilege outpatient and day care treatment. All in all, 
the total budget allocated to both inpatient and outpatient 
drug-treatment was massively reduced between 2008 and 
2010. Since 2008, the government has also increased the 
patient co-payment for drug treatment. Furthermore, the 
capacity of the national rehabilitation programme has also 
been reduced. Up to 2011, with the help of international 
support, the government scaled up harm reduction and 
methadone treatment. However, the cessation of international 
support to these projects, in 2011, has raised doubts about the 
country’s capacity to maintain them at previous levels. The 
limited and diminishing coverage of harm-reduction services 
has been indicated as a risk factor (EMCDDA, 2014a). 
In Ireland, funds labelled to finance drug-related policies for 
health have registered marked falls since 2008 (by 12 % in 
2009, 1 % in 2010 and 13 % in 2011, in real terms). In 2012, 
there were expectations that funding for some drug-related 
initiatives would be reduced further.
In a number of countries where quantitative information is 
limited or unavailable, there are some reports describing 
changes to services arising from austerity measures. In 
Slovakia, in 2012, the lack of competitive salaries paid to 
doctors in the drugs field has been suggested to have led to a 
decrease in the supply and coverage of residential treatment. 
In Spain, recent reports suggest that public austerity is 
impacting on the provision of health care across many Spanish 
regions. Examples are given of cuts in funding to and the 
reorganisation of HIV/AIDS prevention and treatment services, 
which may jeopardise effectiveness (European AIDS Treatment 
Group, 2014b). In Portugal, austerity has also been a priority 
for the government. In 2011–12, without changing the types of 
(9)  The European Union increased the transfers of funds to Greek harm-reduction 
initiatives, within the framework of the European Funds for Cohesion Policy. 
provision did not decline after 2008, concerns have been 
voiced about the financing of rehabilitation programmes, with 
suggestions that capped budgets were limiting programme 
availability and leading to reductions in lengths of stay.
In the countries where the recession had a moderate impact 
(Groups 2 and 3), the picture appears more diverse. While 
some countries introduced cuts in the financing of drug-
related health interventions after 2008, others continued 
increasing the funds available for some types of drug 
treatment. It appears that in most cases where cuts occurred, 
a return to growth in expenditure was quite rapid.
For instance, in Estonia, between 2009 and 2010, the 
government set the protection of funding for drug treatment 
and rehabilitation as a priority during the economic downturn. 
Indeed, funds available for opioid substitution therapy 
continued growing as did those for treating the new 
population of amphetamine users. Nevertheless, the funding 
of primary prevention and harm reduction declined, and funds 
available for syringe exchange programmes, voluntary testing 
and counselling for HIV and other drug-related infections 
diminished. In 2011, the mild national economic recovery 
allowed this trend to reverse, and the financing of syringe 
exchange programmes started rising again. In Finland, funds 
for health declined overall in 2010, when a reduction in funds 
available for specialist medical care more than offset a sharp 
increase in primary health care funding. In 2011, drug-related 
expenditure on health resumed increasing, surpassing the 
growth rate observed for overall spending on health. In 
Slovenia, in the context of efforts to rationalise overall health 
care, the number of acute drug-related cases admitted to 
hospital declined in 2010, leading to savings and partially 
explaining the cut in drug-related health expenditure observed 
in 2010 and the following year. In 2012, this funding increased 
again. In the United Kingdom, the information available is 
partial and concerns only labelled expenditure. Data suggest 
that, in 2010, less funding was allocated to drug-related health 
budgets, when compared to the previous year (down by 4 % in 
2010, in real terms). More recently, from April 2013, the 
previously ring-fenced drug-related treatment budget in 
England has been subsumed into a wider public health grant 
allocation to local areas. As a range of services are funded 
through the public health grant, there are concerns by some 
that funds previously spent on drug treatment might be 
diverted to address other public health needs. Local 
authorities have been required to report their annual global 
forecasted and actual expenditure on drug treatment. 
However, as the data collection is a new exercise and there are 
currently no requirements to report a more detailed 
breakdown of expenditure, a comprehensive analysis of drug 
treatment costs becomes difficult at this time. France is an 
exception to the general picture, since total public expenditure 
on health and on drug-related health initiatives continued to 
grow, although at a more moderate pace than before.
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represents a significant percentage of public order and safety 
expenditure (about 10 %), the budgetary objectives of supply 
reduction may be more closely integrated into the spending 
strategy defined for the overall budgets of police, law courts 
and prisons and, therefore, more aligned with the overall 
objectives defined for public policy in comparison with the 
objectives defined for demand reduction initiatives.
Expenditure on research
Research is one sector of drug-related activity that has been 
reported as being particularly affected by lack of funds. 
However, the timing of the impact of the recession on research 
has been delayed compared to that on other sectors, with many 
countries indicating 2012 as the year the effect was first felt on 
research. For 2009 and 2010, only Cyprus, mentioned funding 
cuts for research, which led to the postponement of planned 
studies of alcohol strategies and policies for drug prescription 
in 2010. The situation changed in 2012, with 12 national 
reports mentioning problems in research funding. Croatia and 
Poland mentioned an insufficiency of funds for analysis of new 
psychoactive substances and research on drug markets and 
drug monitoring. Specific budget cuts were mentioned by 
Greece, by Germany regarding the funding of research 
networks and by Cyprus and Romania as a reason to postpone 
or suspend research on mortality and risk reduction. The Czech 
Republic and Finland reported that budget cuts primarily 
affected research projects or the allocation of research 
subvention schemes. From a different perspective, Ireland 
mentioned that one study was carried out in anticipation of a 
decline in funding, to evaluate the effectiveness and efficiency 
of 30 projects funded by a regional drug task force.
In contrast, two countries reported new financial resources: 
Slovakia, for the implementation of research services; and 
Sweden, for compiling research and evaluation of 
interventions on the use of drugs, particularly cannabis.
I  Strategies to limit the impact of recession  on the drug situation
After the 2008 recession, some governments adopted specific 
policy strategies either to limit the potential damage of 
austerity or to take advantage of the adverse period to improve 
efficiency. However, in most cases, it is not yet possible to 
assess the effectiveness of these attempts, because policy 
changes require time to provide results. 
In response to the recession, some countries announced an 
intention to ring-fence expenditure on specific sectors, such 
as health or social protection, aiming to limit the potential 
negative impact of austerity on these areas (Mladovsky et al., 
2012; OECD, 2012a; OECD, 2012c; OECD, 2012d). The Czech 
drug-related interventions provided, the government 
reorganised the system of drug-related health, and preliminary 
information suggests that expenditure may have been reduced 
in some areas, including the national programme addressing 
HIV transmission. Difficulties in gaining access to drug-related 
prevention and treatment were reported, such as temporary 
shortages of medication or syringes (European AIDS 
Treatment Group, 2014a). In Romania, it has been reported 
that reductions in funding might be associated with an 
outbreak of HIV observed in 2010. Failure to provide national 
funding for prevention programmes previously financed by 
international donors resulted in a temporary, substantial 
reduction of funds and, consequently, reduced the coverage of 
HIV prevention services; this coincided with an HIV outbreak. 
The numbers of syringes given out dropped from 1.7 million in 
2009 to under one million in 2010 and 2011, although 
additional funds were raised to increase syringe provision in 
2012 to above one million. More recently, the main harm-
reduction service provider (ARAS) has had to halve service 
provision since July 2013 (EMCDDA, 2014a).
In the area of drug-use prevention, some country reports 
suggest that reduced funding may have led to a decrease in 
interventions and human resources. There are, however, few 
estimates of cuts to expenditure and no cost-effectiveness 
analysis has been performed. In Portugal, there are some 
preliminary indications that labelled expenditure for the 
prevention and harm-reduction systems decreased in 2011 
and 2012. Similarly, in Latvia, Hungary, Austria and Slovakia, 
budget cuts were indicated as being one of the obstacles to 
the expansion of selective and indicated prevention 
interventions, which involve direct contact with vulnerable 
groups. In the Czech Republic, primary prevention was 
identified as the sector most affected by cuts.
Supply reduction expenditure
Only eight countries have provided information for the trends 
in expenditure on supply reduction initiatives, probably 
because most of this expenditure is embedded in broader and 
more general programmes against crime, being therefore 
more difficult to estimate (see the box ‘Overview of drug-
related public expenditure data in Europe’). In six of these 
countries, expenditure on drug supply reduction followed 
approximately the overall trend in expenditure on public order 
and safety. This may reflect the fact that drug supply reduction 
initiatives are not isolated from the broader and more general 
set of programmes and actions against crime. Furthermore, 
supply reduction activity is frequently financed or provided by 
central government, with the result that spending on these 
sub-sectors (police, courts and prisons) may be more readily 
controlled than in sectors where service provision is more 
likely to be distributed across different levels of government. 
Last but not least, since in many countries supply reduction 
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Public austerity and limited resources have also contributed to 
debates on the quality of the overall health provision systems 
and about cost-effectiveness in health provision in some 
countries. For instance, in Ireland, the government undertook 
a needs-assessment programme to improve the cost-
effectiveness of services. As a consequence and in order to 
improve cost-effectiveness for drug treatment, the 
government set a roadmap proposing some main targets. 
First, to increase the coverage of the opioid substitution 
treatment programmes to a rate close to 100 %; second, to 
introduce local service provision at standards comparable to 
those in Dublin; and third, to increase the availability of mental 
health services to drug users. For rehabilitation programmes, 
the government recommended a more efficient administrative 
system for clients. In the United Kingdom, specific tools are 
available to allow local authority drug treatment 
commissioners to estimate and improve the social return on 
investment of drug treatment provision in their area. For 
example, English local authorities have had at their disposal 
for some years a ‘value for money tool’, but perhaps it has 
increased utility in the climate of austerity.
I Conclusion
The 2008 world economic recession had a major impact on 
many European countries, pushing up unemployment rates to 
unusually high levels and forcing governments to consolidate 
public accounts. This fiscal consolidation was mostly achieved 
at the expense of public expenditure, with total European 
public spending declining in 2011 and 2012, in real terms, in 
contrast to the annual growth rates of close to 2 % registered 
in the previous decade. 
Austerity led to reductions in spending in those categories of 
government activity that encompass most drug-related 
initiatives, namely health, social protection and public order 
and safety. As drug-related expenditure represents a small 
proportion of these aggregates, it cannot be directly inferred 
that public spending on drug initiatives necessarily behaved 
similarly. Reductions in funding for these areas of activity, 
however, may have an indirect impact on drug-related 
initiatives.
The level of austerity has differed considerably across 
countries and sectors in Europe. Between 2009 and 2011, the 
countries that experienced greater levels of austerity tended 
to show greater reductions in expenditure in the three sectors 
that cover most drug-related activities. Public spending on 
health registered bigger cuts than public safety and social 
protection. The OECD suggests that although cuts in health 
may have been unavoidable, some measures may have an 
impact on the ability of health systems to meet fundamental 
goals and, therefore, highlights the need to monitor closely 
government made this concern explicit when they announced 
the intention to ring-fence expenditure on health and social 
protection. This overall goal seems to have been achieved, as 
there was positive growth in expenditure in 2010 and 2011 in 
both sectors. However, despite this, drug-related health 
expenditure, both labelled and unlabelled, fell in 2009 and in 
2011. In 2010, attempts to ring-fence treatment funds were 
relatively successful, but priorities were changed: in order to 
make programmes provided by governmental organisations 
(as distinct from those provided by non-governmental 
organisations) more likely to be eligible for funding; to reduce 
the financing of international cooperation; and to drastically 
reduce funding of research projects. 
In Estonia, the government ring-fenced the funding of drug-
treatment and rehabilitation in 2009 and 2010; estimates 
suggest that, in those years, the funding of opioid substitution 
treatment and amphetamine therapies continued to grow. 
However, the funding of other harm-reduction initiatives such 
as syringe exchange programmes, voluntary testing and 
counselling for HIV and other infections fell until 2011, when 
this trend started to turn. In the United Kingdom, the 
government sought to protect public spending on health. Data 
available for estimated labelled drug-related public 
expenditure, which made up 13 % of estimated total drug-
related expenditure but 74 % of drug-related health 
expenditure in 2010, show that funding for some areas of 
drug-related budgets (such as the pooled treatment budget in 
England and the budget for drug treatment in prisons) 
remained constant in nominal terms. However, in the United 
Kingdom, the total estimated labelled funding allocated to 
drug-related initiatives in the health sector fell by 4 % in 2010, 
in real terms, compared to 2009. 
Instead of, or alongside, ring-fencing, tighter resources have 
led some countries to strive for more quality control and 
evidence-based funding. In Ireland, the government sought to 
better apply quality standards to prevention programmes and 
to focus resources on at-risk populations, with targeted 
interventions. The Czech Republic changed its grant system 
for prevention initiatives, merging it into a single grant scheme, 
where the Ministry of Education is the sole donor. This, in turn, 
allowed the introduction of the first certification system in the 
European Union, in which only certified programmes can 
apply for these funds. An additional certification of 
professionals improves the likelihood of prevention 
programmes being delivered with better quality and public 
funds being spent more efficiently, avoiding the drainage of 
funds by interventions with no or poor evidence of 
effectiveness. Partly in line with the same trend, over one-third 
of European countries have now reduced or abandoned mass 
media drug prevention campaigns (10). 
(10)  Belgium, Estonia, Cyprus, Luxembourg, Hungary, Malta, Netherlands, Austria, 
Portugal, Slovakia, Norway.
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inpatient drug treatment; and attempts to increase the 
cost-effectiveness of health provision through reorganisation. 
In a few countries, cuts in the international co-financing of 
drug services have introduced additional difficulties. The 
impact of all these changes will probably not be unidirectional 
and will take time before becoming visible. 
The effectiveness of drug policy is influenced by social and 
policy factors, among others, which prevents a clear-cut 
analysis of the impact of the public austerity. The complexity 
of this phenomenon can be illustrated in countries such as 
Greece, where HIV outbreaks have occurred among problem 
drug user groups. There, although it is likely that the economic 
recession contributed to the outbreaks, other systemic factors 
were crucial. Among the relevant factors for a comprehensive 
understanding of the outbreaks — other than recession — are 
the epidemiological situation, the level of drug-treatment, the 
degree of harm-reduction coverage, social integration policies 
and the level of income inequality within societies.
Drug prevention is reported to be a sector that has been the 
subject of cuts in financing. On the one hand, reduced funds 
have led to the downsizing of prevention programmes; on the 
other hand, the reduction in funds has increased awareness of 
the need of more quality control and evidence-based funding. 
All in all, the medium-term impact of austerity is still to be 
assessed. Drug-related research has also registered cuts in 
many countries.
In line with the overall trend detected in most countries after 
the economic recession, drug-related expenditure on social 
protection has also been reduced in those countries 
presenting estimates for this component. However, as many 
countries either present no data or insufficient data, 
conclusions cannot be drawn about the likely extent of any 
impact. This is of concern, given the research evidence on the 
negative impact of recessions on mental health. Tackling the 
risk factors for mental health problems, such as 
unemployment and poverty, which may result from the 2008 
economic recession, requires an integrated public policy, 
where employment policies are coordinated with such broad 
types of interventions as family support or debt relief 
programmes. 
Public expenditure on public order and safety, which finances 
most supply reduction activities in the drugs field, declined 
markedly in real terms after 2008, especially in 2011. The 
number of countries providing estimates for total drug-related 
expenditure on supply reduction initiatives is especially small, 
because these expenditures are mostly unlabelled, embedded 
in broader categories of public spending and therefore difficult 
to identify. Within the group of countries presenting these 
estimates, all but one reported either short-term or lasting 
reductions in the funds allocated. 
their consequences. The OECD (2014) concluded that, ‘It is 
still too early to quantify the longer-term effects on people’s 
health, but unemployment and economic difficulties are 
known to contribute to a range of health problems, including 
mental illness… Short-term savings may translate into much 
higher costs in the future, and governments should make 
funding of investment-type programmes a priority. Today’s 
cuts in health spending need to avoid triggering rising health 
care needs tomorrow… Maintaining and strengthening 
support for the most vulnerable groups must remain a crucial 
part of any strategy for an economic and social recovery. 
Governments need to time and design any fiscal consolidation 
measures accordingly, as the distributional impact of such 
measures can vary greatly: for example, the poor may suffer 
more from spending cuts than from tax increases.’
The available national estimates of drug-related public 
expenditure do not reveal the full impact of the 2008–09 
economic recession on the public financing of drug policy in 
Europe. However, one conclusion can safely be drawn: 
reductions in overall funding for the provision of public 
services such as public order and safety, health and social 
protection are likely to impact negatively on the capacity to 
deliver drug services and drug law enforcement, since these 
are areas that have synergies with drug-related interventions. 
Bearing in mind the limitations of the available data, some 
tentative conclusions may be drawn. As was the case in other 
fields of public policy, the impact of austerity on drug policy 
was more severe in the countries that were hardest hit by the 
economic crisis. Nevertheless, in most European countries, 
the public financing of specific drug policies has been 
reassessed and often adjusted.
One characteristic that seems to be shared by most European 
countries is that after 2008, policymakers and planners faced 
more uncertainty concerning future financing. Budgets 
became more likely to be subject to revision, often resulting in 
cuts. On the one hand, this introduced additional difficulties 
because plans were more difficult to make; on the other hand, 
these difficulties have raised policymakers’ awareness of the 
need for more cost-effective policy measures. In some 
countries, reorganisation of the sectors of health, social 
protection, or both, as well as drug services has been 
attempted. 
Many European countries, spanning the full range of impact of 
the recession, have reassessed the financing of their health 
sector. While numerous countries mentioned the aim of 
ring-fencing health expenditure, only a few achieved it. 
Austerity led to different outcomes in different countries. 
Among the changes reported by some countries are the 
following: reorganisation of drug-related treatment and 
harm-reduction services; changes in co-financing systems; a 
shift towards outpatient treatment or day-care treatment over 
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Nevertheless, in a framework where austerity has affected the 
main sectors covering and financing drug policy, especially in 
those countries most severely hit by the economic recession, 
policymakers will wish to focus on policies that have proven to 
be most effective and to be alert to any emerging problems. 
This reiterates the importance of having better data available 
and following the phenomenon closely. The potential negative 
impact of the 2008 economic recession on the drug 
phenomenon has been stressed by the international 
community. In 2014, The Commission on Narcotic Drugs of the 
United Nations agreed upon a joint resolution highlighting the 
need to provide sufficient health services to individuals 
affected by substance disorders during long-term and 
sustained economic downturns (United Nations, 2014). The 
United Nations encourages countries to ensure that responses 
to downturns do not disproportionately affect national drug 
demand and supply reduction policies. Countries are also 
encouraged to guarantee adequate provision of related health 
measures and supply reduction efforts. Finally, countries are 
invited to continue providing, including in times of downturn, 
the best attainable coverage, accessibility and quality of 
health and social services to those who are or may be affected 
by drug problems.
This report has attempted to provide important insights into 
the likely impact of the recession on the drug phenomenon in 
Europe. It notes, nevertheless, that information concerning the 
full impact of the 2008 recession on funds available for 
drug-related policies is still not available, partly because the 
number of countries with data for drug-related public 
expenditure in 2012 is very small. In addition, according to 
global economic indicators, 2012 was still a year of cuts in 
public expenditure in Europe. It should also be noted that the 
impact of changes in funding arrangements may take time to 
fully impact on the provision of public services; therefore the 
full impact is still to come. Furthermore, and by the same 
token, the most common types of outcomes used for 
assessing the cost-effectiveness of drug-related health 
interventions (such as the amounts and types of substance 
use, treatment retention rates, mental and physical health 
status as well as quality of life status measured at the end of 
treatment) will only become visible after some time. Therefore, 
a full analysis will only be possible after some period of delay. 
Consequently, the contours of the impact of the 2008 
economic recession will take time to be fully known. Improving 
data available of national drug-related public expenditure 
would be a valuable and necessary asset for future 
assessments.
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I  Automatic stabilisers are budgetary measures that dampen fluctuations in real GDP, automatically 
triggered by the tax code and by spending rules.
I  Cost-effectiveness analysis involves estimating the ratio of the difference in costs between two 
alternatives (net costs) divided by the difference of their outcomes (Gold et al., 1996). For instance, 
Chalk et al. (2013) define the cost-effectiveness of opioid substitution treatment as the incremental 
price of obtaining a unit health effect (e.g. 10 % reduction in days of opioid use in the past month) 
from a given health intervention (e.g. counselling and methadone) when compared to an alternative 
(e.g. counselling alone).
I  Cyclically adjusted primary budget balance is the cyclically adjusted balance excluding payments of 
public debt. The cyclically adjusted balance is the difference between the current balance and the 
automatic stabilisers; equivalently, an estimate of the fiscal balance that would apply under current 
policies if output were equal to potential. The current balance is the difference between the money 
received by the government in tax and public expenditure of the value of the goods and services 
consumed for purposes other than investment.
I  Economic recession is a period when the economy shrinks. In technical terms, it is usually defined as 
six months of economic contraction (a fall in the gross domestic product for two consecutive 
quarters, on a quarter on quarter basis). A recession becomes a depression if it is unusually deep and 
long-lasting, such as the Great Depression that struck in the 1930s (Keely and Love, 2010).
I  Fiscal consolidation is defined as concrete policies aimed at reducing government deficits and debt 
accumulation. During an economic recession, governments may also decide to take special — or 
‘discretionary’ — actions to restore growth or public finances. Virtually every country did so after 
2008, although the size and scope of the packages varied greatly. Governments in some countries 
introduced fiscal packages to stimulate economic growth; others, with more acute fiscal solvency 
concerns, tightened up their fiscal position by reducing spending (OECD, 2011).
I  Fiscal policy is a tool that governments typically use to steer economies. In simple terms, fiscal policy 
refers to government spending and tax collection. 
I  Government deficit (also known as a budget deficit) exists when a government spends more in a year 
than it earns. Government deficits tend to increase during recessions. First, because governments 
earn less from tax (for example, people buy fewer goods and, therefore, pay less consumption taxes 
or falling profits imply less taxes paid by private companies). Second, because of the existence of the 
social safety net, there is an automatic increase in government spending on items like unemployment 
benefits, as more people lose their jobs. These factors tend to act without requiring special 
government intervention. 
I  Government expenditure refers to the expenditure of the total general government: it includes the 
expenditure of central, regional and local governments as well as social security.
I  Labelled drug-related expenditure is the ex-ante planned public expenditure made by general 
government in the budget that reflects the public and voluntary commitment of a country in the field 
of drugs.
I  Public expenditure refers to the value of goods and services purchased by the general government of 
a state in order to perform each of its functions. The functions of governments are, among others, the 
provision of health care, justice, public order, education and social protection. Public expenditure 
studies are important because they provide information about the size and the composition of costs 
of public programmes and interventions. 
I  Total drug-related public expenditure is the sum of the labelled and unlabelled drug-related 
expenditure.
I  Unlabelled drug-related expenditure is the non-planned or non-publicly announced ex-post public 
expenditure incurred by the general government in tackling drugs that is not identified as drug-
related in the budget.
Glossary
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I Appendix – Country data
TABLE A1
Yearly growth of gross domestic product, volume (%)
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
EU27 3.9 2.1 1.3 1.5 2.5 2.1 3.3 3.2 0.3 −4.3 2.1 1.6 −0.3
Belgium 3.7 0.8 1.4 0.8 3.3 1.8 2.7 2.9 1.0 −2.8 2.4 1.8 −0.3
Bulgaria 5.7 4.2 4.7 5.5 6.7 6.4 6.5 6.4 6.2 −5.5 0.4 1.8 0.8
Czech Republic 4.2 3.1 2.1 3.8 4.7 6.8 7.0 5.7 3.1 −4.5 2.5 1.9 −1.3
Denmark 3.5 0.7 0.5 0.4 2.3 2.4 3.4 1.6 −0.8 −5.7 1.6 1.1 −0.5
Germany 3.1 1.5 0.0 −0.4 1.2 0.7 3.7 3.3 1.1 −5.1 4.2 3.0 0.7
Estonia 9.7 6.3 6.6 7.8 6.3 8.9 10.1 7.5 −4.2 −14.1 3.3 8.3 3.2
Ireland 10.7 5.3 5.6 3.9 4.4 5.9 5.4 5.4 −2.1 −5.5 −0.8 1.4 0.9
Greece 3.5 4.2 3.4 5.9 4.4 2.3 5.5 3.5 −0.2 −3.1 −4.9 −7.1 −6.4
Spain 5.0 3.7 2.7 3.1 3.3 3.6 4.1 3.5 0.9 −3.7 −0.3 0.4 −1.4
France 3.7 1.8 0.9 0.9 2.5 1.8 2.5 2.3 −0.1 −3.1 1.7 2.0 0.0
Croatia 3.8 3.7 4.9 5.4 4.1 4.3 4.9 5.1 2.1 −6.9 −2.3 0.0 −2.0
Italy 3.7 1.9 0.5 0.0 1.7 0.9 2.2 1.7 −1.2 −5.5 1.7 0.4 −2.4
Cyprus 5.0 4.0 2.1 1.9 4.2 3.9 4.1 5.1 3.6 −1.9 1.3 0.5 −2.4
Latvia 5.7 7.3 7.2 7.6 8.9 10.1 11.2 9.6 −3.3 −17.7 −0.9 5.5 5.6
Lithuania 3.6 6.7 6.8 10.3 7.4 7.8 7.8 9.8 2.9 −14.8 1.5 5.9 3.7
Luxembourg 8.4 2.5 4.1 1.7 4.4 5.3 4.9 6.6 −0.7 −4.1 2.9 1.7 0.3
Hungary 4.2 3.7 4.5 3.9 4.8 4.0 3.9 0.1 0.9 −6.8 1.3 1.6 −1.7
Malta   0.0 2.4 0.7 −0.3 3.6 2.6 4.1 3.9 −2.6 2.9 1.7 0.8
Netherlands 3.9 1.9 0.1 0.3 2.2 2.0 3.4 3.9 1.8 −3.7 1.6 1.0 −1.0
Austria 3.7 0.9 1.7 0.9 2.6 2.4 3.7 3.7 1.4 −3.8 2.1 2.7 0.8
Poland 4.3 1.2 1.4 3.9 5.3 3.6 6.2 6.8 5.1 1.6 3.9 4.5 1.9
Portugal 3.9 2.0 0.8 −0.9 1.6 0.8 1.4 2.4 0.0 −2.9 1.9 −1.6 −3.2
Romania 2.4 5.7 5.1 5.2 8.5 4.2 7.9 6.3 7.3 −6.6 −1.1 2.2 0.7
Slovakia 1.4 3.5 4.6 4.8 5.1 6.7 8.3 10.5 5.8 −4.9 4.4 3.2 2.0
Slovenia 4.3 2.9 3.8 2.9 4.4 4.0 5.8 7.0 3.4 −7.8 1.2 0.6 −2.3
Finland 5.3 2.3 1.8 2.0 4.1 2.9 4.4 5.3 0.3 −8.5 3.3 2.8 −0.2
Sweden 4.5 1.3 2.5 2.3 4.2 3.2 4.3 3.3 −0.6 −5.0 6.6 3.7 0.8
United Kingdom 4.2 2.9 2.4 3.8 2.9 2.8 2.6 3.6 −1.0 −4.0 1.8 1.0 0.3
Norway 3.3 2.0 1.5 1.0 4.0 2.6 2.3 2.7 0.1 −1.6 0.5 1.2 3.1
Source: Eurostat
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TABLE A2
Net lending (+) or net borrowing (−) of general government as percentage of gross domestic product
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
EU27 0.6 −1.5 −2.6 −3.2 −2.9 −2.5 −1.5 −0.9 −2.4 −6.9 −6.5 −4.4 −3.9
Belgium 0.0 0.4 −0.1 −0.1 −0.1 −2.5 0.4 −0.1 −1.0 −5.5 −3.8 −3.7 −4.0
Bulgaria −0.5 1.1 −1.2 −0.4 1.9 1.0 1.9 1.2 1.7 −4.3 −3.1 −2.0 −0.8
Czech Republic −3.6 −5.6 −6.5 −6.7 −2.8 −3.2 −2.4 −0.7 −2.2 −5.8 −4.8 −3.2 −4.4
Denmark 2.3 1.5 0.4 0.1 2.1 5.2 5.2 4.8 3.2 −2.7 −2.5 −1.8 −4.1
Germany 1.1 −3.1 −3.8 −4.2 −3.8 −3.3 −1.6 0.2 −0.1 −3.1 −4.1 −0.8 0.1
Estonia −0.2 −0.1 0.3 1.7 1.6 1.6 2.5 2.4 −2.9 −2.0 0.2 1.1 −0.2
Ireland 4.7 0.9 −0.4 0.4 1.4 1.7 2.9 0.1 −7.4 −13.9 −30.9 −13.1 −8.2
Greece −3.7 −4.5 −4.8 −5.6 −7.5 −5.2 −5.7 −6.5 −9.8 −15.6 −10.7 −9.5 −9.0
Spain −0.9 −0.5 −0.2 −0.3 −0.1 1.3 2.4 1.9 −4.5 −11.2 −9.7 −9.6 −10.6
France −1.5 −1.5 −3.1 −4.1 −3.6 −2.9 −2.3 −2.7 −3.3 −7.5 −7.1 −5.3 −4.8
Italy −0.8 −3.1 −3.1 −3.6 −3.5 −4.4 −3.4 −1.6 −2.7 −5.4 −4.5 −3.8 −3.0
Cyprus −2.3 −2.2 −4.4 −6.6 −4.1 −2.4 −1.2 3.5 0.9 −6.1 −5.3 −6.3 −6.4
Latvia −2.8 −2.0 −2.3 −1.6 −1.0 −0.4 −0.5 −0.4 −4.2 −9.8 −8.1 −3.6 −1.3
Lithuania −3.2 −3.5 −1.9 −1.3 −1.5 −0.5 −0.4 −1.0 −3.3 −9.4 −7.2 −5.5 −3.2
Luxembourg 6.0 6.1 2.1 0.5 −1.1 0.0 1.4 3.7 3.2 −0.8 −0.8 −0.3 −0.6
Hungary −3.0 −4.1 −9.0 −7.3 −6.5 −7.9 −9.4 −5.1 −3.7 −4.6 −4.4 4.3 2.0
Malta −5.8 −6.4 −5.8 −9.2 −4.7 −2.9 −2.8 −2.3 −4.6 −3.9 −3.6 −2.7 −3.3
Netherlands 2 −0.2 −2.1 −3.1 −1.7 −0.3 0.5 0.2 0.5 −5.6 −5.1 −4.3 −4.1
Austria −1.7 0.0 −0.7 −1.5 −4.4 −1.7 −1.5 −0.9 −0.9 −4.1 −4.5 −2.5 −2.5
Poland −3.0 −5.3 −5.0 −6.2 −5.4 −4.1 −3.6 −1.9 −3.7 −7.4 −7.9 −5.0 −3.9
Portugal −3.3 −4.8 −3.4 −3.7 −4.0 −6.5 −4.6 −3.1 −3.6 −10.2 −9.8 −4.3 −6.4
Romania −4.7 −3.5 −2.0 −1.5 −1.2 −1.2 −2.2 −2.9 −5.7 −9.0 −6.8 −5.6 −3.0
Slovakia −12.3 −6.5 −8.2 −2.8 −2.4 −2.8 −3.2 −1.8 −2.1 −8.0 −7.7 −5.1 −4.5
Slovenia −3.7 −4.0 −2.4 −2.7 −2.3 −1.5 −1.4 0.0 −1.9 −6.0 −5.7 −6.3 −3.8
Finland 7.0 5.1 4.2 2.6 2.5 2.9 4.2 5.3 4.4 −2.5 −2.5 −0.7 −1.8
Sweden 3.6 1.5 −1.3 −1.0 0.6 2.2 2.3 3.6 2.2 −0.7 0.3 0.2 −0.2
United Kingdom 3.6 0.5 −2.1 −3.4 −3.5 −3.4 −2.7 −2.8 −5.1 −11.5 −10.2 −7.7 −6.1
Norway   13.5 9.3 7.3 11.1 15.1 18.5 17.5 18.8 10.5 11.0 13.3 13.6
Source: Eurostat 
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TABLE A3
Public expenditure as percentage of gross domestic product
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
EU27 44.7 46.1 46.6 47.2 46.7 46.7 46.2 45.5 47.0 51.0 50.6 49.1 49.3
Belgium 49.1 49.1 49.8 51.0 49.2 51.9 48.5 48.2 49.8 53.7 52.6 53.5 55.0
Bulgaria 41.3 40.6 39.6 39.1 38.6 37.3 34.4 39.2 38.4 41.4 37.4 35.6 35.9
Czech Republic 41.6 43.9 45.6 50.0 43.3 43.0 42.0 41.0 41.1 44.7 43.7 43.2 44.5
Denmark 53.7 54.2 54.6 55.1 54.6 52.8 51.6 50.8 51.5 58.1 57.7 57.6 59.5
Germany 45.1 47.6 47.9 48.5 47.1 46.9 45.3 43.5 44.1 48.3 47.9 45.2 44.7
Estonia 36.1 34.8 35.8 34.8 34.0 33.6 33.6 34.0 39.7 44.7 40.5 37.5 39.5
Ireland 31.1 33.2 33.5 33.2 33.7 33.9 34.5 36.7 42.8 48.1 65.5 47.1 42.6
Greece 47.2 45.8 45.5 45.1 45.9 44.6 45.3 47.5 50.6 54.0 51.4 52.0 53.6
Spain 39.2 38.7 38.9 38.4 38.9 38.4 38.4 39.2 41.4 46.2 46.3 45.7 47.8
France 51.7 51.7 52.9 53.4 53.3 53.6 53.0 52.6 53.3 56.8 56.6 55.9 56.6
Italy 45.9 47.7 47.1 48.1 47.5 47.9 48.5 47.6 48.6 51.9 50.4 49.8 50.6
Cyprus 37.1 38.0 40.0 44.6 42.4 43.1 42.6 41.3 42.1 46.2 46.2 46.3 46.4
Latvia 37.6 35.0 36.0 34.9 35.9 35.8 38.3 36.0 39.1 43.7 43.4 38.4 36.5
Lithuania 39.8 37.5 35.4 33.8 34.0 34.0 34.2 35.3 37.9 44.9 42.3 38.7 36.1
Luxembourg 37.6 38.1 41.5 41.8 42.6 41.5 38.6 36.3 39.1 45.2 43.5 42.6 44.3
Hungary 47.8 47.8 51.5 49.7 49.1 50.1 52.2 50.7 49.2 51.4 50.0 50.0 48.7
Malta 39.5 41.2 41.7 45.6 43.6 43.6 43.2 41.8 43.2 42.5 41.6 41.7 43.4
Netherlands 44.2 45.4 46.2 47.1 46.1 44.8 45.5 45.3 46.2 51.4 51.3 49.9 50.4
Austria 51.9 51.3 50.7 51.3 53.8 50.0 49.1 48.6 49.3 52.6 52.8 50.8 51.7
Poland 41.1 43.8 44.3 44.7 42.6 43.4 43.9 42.2 43.2 44.6 45.4 43.4 42.2
Portugal 41.6 43.2 43.1 44.7 45.4 46.6 45.2 44.4 44.8 49.8 51.5 49.3 47.4
Romania 38.6 36.2 35.0 33.5 33.6 33.6 35.5 38.2 39.3 41.1 40.1 39.5 36.6
Slovakia 52.1 44.5 45.1 40.1 37.7 38.0 36.5 34.2 34.9 41.6 40.0 38.4 37.8
Slovenia 46.5 47.3 46.2 46.2 45.6 45.1 44.3 42.3 44.1 48.7 49.4 49.9 48.1
Finland 48.3 48.0 49.0 50.3 50.2 50.3 49.2 47.4 49.2 56.1 55.8 55.2 56.6
Sweden 55.1 54.5 55.6 55.7 54.2 53.9 52.7 51.0 51.7 54.9 52.3 51.5 52.0
United Kingdom 36.4 39.8 40.9 41.8 42.7 43.4 43.6 43.3 47.1 50.8 49.9 48.0 47.9
Norway 42.3 44.1 47.1 48.2 45.1 41.8 40.0 40.3 39.8 46.0 44.6 43.7 42.5
Source: Eurostat
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TABLE A4
Yearly growth of total public expenditure (%), constant prices
Average 2000–07 2008 2009 2010 2011 2012
EU27 2.0 3.2 4.3 0.7 −2.2 −0.3
Belgium 1.3 2.8 5.6 0.2 2.0 2.0
Bulgaria 6.6 3.6 4.5 −8.8 −2.2 0.5
Czech Republic 3.8 0.9 4.7 −0.8 −1.1 1.6
Denmark 1.1 1.7 4.4 2.5 −0.3 2.8
Germany 0.0 1.7 4.5 2.3 −3.3 −0.5
Estonia 7.1 8.1 −1.7 −8.4 0.5 9.2
Ireland 6.5 8.2 7.3 35.6 −27.1 −10.3
Greece 4.7 5.8 3.6 −10.0 −6.9 −4.7
Spain 4.0 5.4 7.9 −1.0 −3.1 1.3
France 2.0 1.0 4.0 1.1 0.3 1.3
Italy 1.2 0.2 2.5 −2.1 −1.3 −1.4
Cyprus 5.6 5.6 6.5 1.1 −0.3 −2.8
Latvia 8.0 0.8 −9.3 −1.0 −5.6 1.7
Lithuania 6.7 7.3 −5.4 −4.3 −1.3 −3.2
Luxembourg 4.5 4.1 8.0 4.1 1.6 4.6
Hungary 3.7 −2.2 −1.7 −2.4 1.2 −5.4
Malta 3.1 6.5 −4.1 1.5 2.9 5.2
Netherlands 2.0 4.2 6.7 1.0 −2.0 −0.8
Austria 0.9 2.4 3.1 1.8 −2.2 1.6
Poland 4.6 6.5 6.0 4.4 −1.4 −2.1
Portugal 2.2 0.0 9.9 5.1 −6.9 −7.1
Romania 8.2 13.2 −1.7 −3.1 1.3 −5.8
Slovenia 3.0 6.5 4.0 1.0 0.4 −6.9
Slovakia 1.0 6.2 11.5 0.0 −3.1 −1.8
Finland 1.6 3.0 3.8 1.0 0.9 1.6
Sweden 1.0 0.7 1.3 1.0 0.9 1.1
United Kingdom 4.6 7.1 2.8 −0.4 −3.6 −0.1
Norway 3.2 4.6 4.9 1.6 2.8 2.4
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TABLE A5
Yearly growth rate of public expenditure on health (%), constant prices
Average 2000–08 2009 2010 2011
EU27 3.4 5.0 −0.1 −1.0
Belgium 3.2 5.8 1.3 2.7
Bulgaria 15.0 −9.7 11.9 0.8
Czech Republic 3.6 7.5 2.4 0.4
Denmark 3.5 5.4 −0.6 −1.2
Germany 1.9 5.3 0.7 0.3
Estonia 8.3 −7.0 −3.3 2.2
Ireland 7.5 3.7 −4.1 −6.3
Greece 12.3 1.2 −9.5 −22.3
Spain 5.5 8.6 −3.9 −4.8
France 2.8 3.5 2.4 2.3
Italy 3.5 1.4 0.2 −2.7
Cyprus 4.7 6.6 2.2 2.2
Latvia 10.6 −17.2 −11.4 5.0
Lithuania 8.3 −9.9 0.3 3.9
Luxembourg 5.4 7.4 1.1 −0.4
Hungary 2.8 −2.7 2.4 1.3
Malta 3.9 −0.9 3.7 5.4
Netherlands 7.1 8.8 2.1 2.4
Austria 1.0 2.5 0.8 −3.1
Poland 8.0 4.3 −0.2 −2.3
Portugal 2.1 9.2 −5.5 −1.6
Romania 7.5 11.6 −6.3 −3.4
Slovakia 9.3 5.1 −14.9 −6.0
Slovenia 3.4 6.6 −3.1 −1.1
Finland 4.4 3.3 1.1 1.3
Sweden 3.4 2.6 1.2 3.0
United Kingdom 5.9 6.9 −0.6 −2.5
Norway 3.7 3.0 2.2 3.3
Source: Eurostat.
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TABLE A6
Yearly growth rate of public expenditure on social protection (%), constant prices
Average 2000–08 2009 2010 2011
EU27 1.9 6.7 1.0 −0.7
Belgium 1.9 7.4 0.3 1.4
Bulgaria 5.8 17.8 −0.1 −1.6
Czech Republic 3.6 6.1 0.2 0.9
Denmark 1.5 5.0 3.8 −0.4
Germany −0.1 5.2 −0.2 −2.6
Estonia 7.0 16.7 −5.3 −4.2
Ireland 7.0 15.4 2.1 0.1
Greece 3.9 5.5 −3.3 −0.4
Spain 4.4 12.4 2.8 −1.3
France 2.3 4.7 1.5 1.2
Italy 1.5 4.8 1.0 −0.3
Cyprus 6.8 8.8 7.7 2.9
Latvia 2.3 19.3 −3.2 −5.9
Lithuania 6.7 9.8 −11.6 −5.7
Luxembourg 4.9 8.9 3.7 1.5
Hungary 4.7 −1.7 −4.1 −1.9
Malta 3.8 3.7 1.0 3.2
Netherlands 1.4 6.8 2.8 0.4
Austria 1.2 5.2 1.7 −1.5
Poland 2.5 8.3 5.0 −2.8
Portugal 4.5 12.4 2.3 −2.2
Romania 9.2 10.5 1.4 −2.2
Slovakia 0.8 13.4 3.4 −0.8
Slovenia 3.1 6.4 2.0 1.3
Finland 1.4 7.1 1.7 1.1
Sweden 0.9 3.5 0.0 −0.9
United Kingdom 3.2 7.5 1.6 −0.5
Norway 3.9 6.3 2.7 4.5
Source: Eurostat.
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TABLE A7
Yearly growth rate of public expenditure on public order and safety (%), constant prices
Average 2000–08 2009 2010 2011
EU27 2.4 3.1 0.4 −2.1
Belgium 3.2 3.6 1.2 −0.2
Bulgaria 10.4 5.0 −10.5 −2.7
Czech Republic 1.9 1.6 −1.0 −9.7
Denmark 3.2 2.1 −1.6 1.2
Germany 0.2 4.5 0.4 0.7
Estonia 6.7 −27.4 −0.7 1.6
Ireland 5.5 −3.0 −2.2 −3.0
Greece 17.4 12.4 −9.7 −12.7
Spain 4.9 1.7 5.1 −4.2
France 3.0 7.0 1.2 1.1
Italy −0.1 6.0 1.1 −1.3
Cyprus 5.0 4.7 6.3 −6.0
Latvia 7.3 −26.6 −6.8 0.4
Lithuania 5.9 −17.9 3.5 6.8
Luxembourg 5.3 3.8 8.4 5.1
Hungary 4.2 −8.4 −3.7 3.2
Malta 1.7 1.6 −0.5 1.2
Netherlands 4.4 5.1 −2.1 −1.0
Austria 1.2 2.9 −0.9 −1.3
Poland 10.2 3.0 1.2 −2.4
Portugal 2.5 7.4 −0.1 −4.8
Romania 14.2 −9.6 11.1 −6.3
Slovenia 3.0 1.8 3.3 −7.6
Slovakia 2.7 10.6 12.9 −5.4
Finland 1.8 2.8 5.4 −1.4
Sweden 2.2 1.2 4.9 0.7
United Kingdom 5.2 1.8 −3.0 −5.5
Norway 2.3 4.4 2.8 4.2
Source: Eurostat 
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TABLE A8
Unemployment rate (%), annual average
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
EU27 8.8 8.6 8.9 9.1 9.3 9.0 8.3 7.2 7.1 9.0 9.7 9.7 10.5
Belgium 6.9 6.6 7.5 8.2 8.4 8.5 8.3 7.5 7.0 7.9 8.3 7.2 7.6
Bulgaria 16.4 19.5 18.2 13.7 12.1 10.1 9.0 6.9 5.6 6.8 10.3 11.3 12.3
Czech Republic 8.8 8.1 7.3 7.8 8.3 7.9 7.1 5.3 4.4 6.7 7.3 6.7 7.0
Denmark 4.3 4.5 4.6 5.4 5.5 4.8 3.9 3.8 3.4 6.0 7.5 7.6 7.5
Germany 8.0 7.9 8.7 9.8 10.5 11.3 10.3 8.7 7.5 7.8 7.1 5.9 5.5
Estonia 13.6 12.6 10.3 10.1 9.7 7.9 5.9 4.6 5.5 13.8 16.9 12.5 10.2
Ireland 4.2 3.9 4.5 4.6 4.5 4.4 4.5 4.7 6.4 12.0 13.9 14.7 14.7
Greece 11.2 10.7 10.3 9.7 10.5 9.9 8.9 8.3 7.7 9.5 12.6 17.7 24.3
Spain 11.7 10.5 11.4 11.4 10.9 9.2 8.5 8.3 11.3 18.0 20.1 21.7 25.0
France 9.0 8.2 8.3 8.9 9.3 9.3 9.2 8.4 7.8 9.5 9.7 9.6 10.2
Italy 10.0 9.0 8.5 8.4 8.0 7.7 6.8 6.1 6.7 7.8 8.4 8.4 10.7
Cyprus 4.8 3.9 3.5 4.1 4.6 5.3 4.6 3.9 3.7 5.4 6.3 7.9 11.9
Latvia 13.7 12.9 12.8 11.3 11.2 9.6 7.3 6.5 8.0 18.2 19.8 16.2 14.9
Lithuania 16.4 17.4 13.8 12.4 11.3 8.0 5.2 3.8 5.3 13.6 18.0 15.3 13.3
Luxembourg 2.2 1.9 2.6 3.8 5.0 4.6 4.6 4.2 4.9 5.1 4.6 4.8 5.1
Hungary 6.3 5.6 5.6 5.8 6.1 7.2 7.5 7.4 7.8 10.0 11.2 10.9 10.9
Malta 6.7 7.6 7.4 7.7 7.2 7.3 6.9 6.5 6.0 6.9 6.9 6.5 6.4
Netherlands 3.1 2.5 3.1 4.2 5.1 5.3 4.4 3.6 3.1 3.7 4.5 4.4 5.3
Austria 3.6 3.6 4.2 4.3 4.9 5.2 4.8 4.4 3.8 4.8 4.4 4.2 4.3
Poland 16.1 18.3 20.0 19.8 19.1 17.9 13.9 9.6 7.1 8.1 9.7 9.7 10.1
Portugal 4.5 4.6 5.7 7.1 7.5 8.6 8.6 8.9 8.5 10.6 12.0 12.9 15.9
Romania 6.8 6.6 7.5 6.8 8.0 7.2 7.3 6.4 5.8 6.9 7.3 7.4 7.0
Slovakia 18.9 19.5 18.8 17.7 18.4 16.4 13.5 11.2 9.6 12.1 14.5 13.6 14.0
Slovenia 6.7 6.2 6.3 6.7 6.3 6.5 6.0 4.9 4.4 5.9 7.3 8.2 8.9
Finland 9.8 9.1 9.1 9.0 8.8 8.4 7.7 6.9 6.4 8.2 8.4 7.8 7.7
Sweden 5.6 5.8 6.0 6.6 7.4 7.7 7.1 6.1 6.2 8.3 8.6 7.8 8.0
United Kingdom 5.4 5.0 5.1 5.0 4.7 4.8 5.4 5.3 5.6 7.6 7.8 8.0 7.9
Norway 3.2 3.4 3.7 4.2 4.3 4.5 3.4 2.5 2.5 3.2 3.6 3.3 3.2
Source: Eurostat
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TABLE A9
Unemployment rate among the under-25s (%)
  2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
EU27 17.6 17.4 18.0 18.5 18.9 18.8 17.5 15.7 15.8 20.1 21.0 21.4 22.9
Belgium 16.7 16.8 17.7 21.8 21.2 21.5 20.5 18.8 18.0 21.9 22.4 18.7 19.8
Bulgaria 33.7 38.3 35.2 26.6 24.3 21.0 18.3 14.1 11.9 15.1 21.8 25.0 28.1
Czech Republic 17.0 16.6 16.0 17.6 20.4 19.3 17.5 10.7 9.9 16.6 18.3 18.1 19.5
Denmark 6.2 8.3 7.4 9.2 8.2 8.6 7.7 7.5 8.0 11.8 13.9 14.2 14.1
Germany 8.7 8.4 9.9 11.6 13.8 15.6 13.8 11.9 10.6 11.2 9.9 8.6 8.1
Estonia 23.9 22.2 17.9 20.9 23.9 15.1 12.1 10.1 12.0 27.4 32.9 22.4 20.9
Ireland 6.7 7.2 8.4 8.7 8.7 8.6 8.7 9.1 13.3 24.0 27.6 29.1 30.4
Greece 29.1 28.0 26.8 26.8 26.5 25.8 25.0 22.7 21.9 25.7 33.0 44.7 55.3
Spain 23.2 21.1 22.2 22.7 22.0 19.6 17.9 18.1 24.5 37.7 41.5 46.2 52.9
France 20.2 19.0 18.9 18.9 20.5 21.0 22.0 19.5 19.0 23.6 23.3 22.6 24.4
Italy 26.2 23.1 22.0 23.6 23.5 24.0 21.6 20.3 21.3 25.4 27.8 29.1 35.3
Cyprus 9.9 8.2 8.0 8.8 10.2 13.9 10.0 10.2 9.0 13.8 16.6 22.4 27.7
Latvia 22.4 22.7 20.3 19.6 20.0 15.1 13.6 10.6 13.6 33.3 36.2 31.0 28.5
Lithuania 30.0 31.1 23.0 24.8 21.8 15.8 10.0 8.4 13.3 29.6 35.7 32.6 26.7
Luxembourg 6.6 6.2 7.0 11.2 16.4 14.6 15.5 15.6 17.3 16.5 15.8 16.4 18.0
Hungary 11.9 11.0 11.9 13.2 15.5 19.4 19.1 18.1 19.9 26.5 26.6 26.1 28.1
Malta 13.7 18.8 17.1 17.4 16.6 16.1 15.5 13.5 11.7 14.5 13.2 13.3 14.1
Netherlands 6.1 5.0 5.4 7.3 9.0 9.4 7.5 7.0 6.3 7.7 8.7 7.6 9.5
Austria 5.3 5.8 6.7 8.1 9.7 10.3 9.1 8.7 8.0 10.0 8.8 8.3 8.7
Poland 35.1 39.5 42.5 41.9 39.6 36.9 29.8 21.6 17.2 20.6 23.7 25.8 26.5
Portugal 10.6 11.6 14.4 18.0 19.1 20.0 20.4 20.6 20.5 25.1 28.2 30.3 37.9
Romania 17.2 17.6 21.0 19.5 21.0 19.7 21.0 20.1 18.6 20.8 22.1 23.7 22.7
Slovakia 37.3 39.6 38.1 33.8 33.4 30.4 27.0 20.6 19.3 27.6 33.9 33.7 34.0
Slovenia 16.3 17.8 16.5 17.3 16.1 15.9 13.9 10.1 10.4 13.6 14.7 15.7 20.6
Finland 21.4 19.8 21.0 21.8 20.7 20.1 18.7 16.5 16.5 21.5 21.4 20.1 19.0
Sweden 10.5 15.0 16.4 17.4 20.4 22.6 21.5 19.2 20.2 25.0 24.8 22.8 23.7
United Kingdom 12.2 11.7 12.0 12.2 12.1 12.8 14.0 14.3 15.0 19.1 19.6 21.1 21.0
Norway 9.8 10.0 10.8 11.2 11.2 11.4 8.8 7.2 7.3 9.2 9.2 8.7 8.6
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